Skip to main content

ValiRx news round-up: January & February 2024

5 Mar 2024


This ValiRx news round-up covers our news, updates, and highlights from January and February.

We were particularly delighted to announce our agreement with Dundee University which will see us streamline the process of reviewing and accessing research from the university’s Drug Discovery Unit. 

If you'd like to discuss any of our updates, please get in touch with ValiRx CEO Dr Suzy Dilly.

Agreement signed with Dundee University

ValiRx has signed an over-arching agreement with the University of Dundee and their Drug Discovery Unit, University of Dundee (DDU) to access research relating to novel therapeutic candidates. 
The first Evaluation Agreement under the framework focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours). This exciting area of research has the potential to be effective in treating multiple cancer types, and many other disease areas, including those associated with healthy ageing. 
This work builds upon previous ground-breaking research by Dundee and Barts Charity funded research by Prof Cleo Bishop, Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility.

The research project has also been featured in the press, with coverage in The Herald. 

Find out more here.

‘Translating to liquid assets’ features in Laboratory News

An article authored by our CEO Suzy Dilly has featured in Laboratory News. The piece describes the journey to building our tCRO Inaphaea BioLabs, including integrating the scientific assets we acquired from Imagen Therapeutics and developing the company’s service offering.

Read the article on pages 19-21 of Issue 1 2024 here. 

Inaphaea on video

Our subsidiary company Inaphaea has launched the first video of its three-part series introducing the company, its collaborations, and its innovative work with PDCs.

Check out ‘Introducing Inaphaea’ here. 


Inaphaea collaborates with DefiniGEN 

Inaphaea’s portfolio of services is consistently growing, and the team recently announced its collaboration with DefiniGEN for profiling drug candidates for liver disease and liver toxicity using their in vitro, IPSC-derived, hepatocyte assays.

DefiniGEN's mission is to navigate drug development programs through uncertain terrain, minimising risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery and development.

Find out more about DefiniGEN’s in-vitro liver cell assay service here.

Laptop keyboard